Patients with severe secondary mitral regurgitation treated with MitraClip and medical therapy have the same rate of death or unplanned hospitalization for heart failure at one year as patients treated with medical therapy alone, results of MITRA-FR show. Abbott, as well as other companies developing transcatheter mitral-repair technology, will now look to the COAPT trial to establish MitraClip's benefits on clinical outcomes.
Patients with severe secondary mitral regurgitation treated with Abbott Laboratories Inc.'s MitraClip had similar one-year outcomes to patients treated with optimal medical management in the MITRA-FR trial.
MITRA-FR primary investigator Jean-Francois Obadia of the Civil Hospices of Lyon in France presented the one-year results of the MITRA-FR,...